Esophageal Cancer - Pipeline Review, H1 2016


#714510

448pages

Global Markets Direct

$ 2000

In Stock

Esophageal Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Esophageal Cancer - Pipeline Review, H1 2016, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Esophageal Cancer - Overview 11
Pipeline Products for Esophageal Cancer - Comparative Analysis 12
Esophageal Cancer - Therapeutics under Development by Companies 13
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Esophageal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Esophageal Cancer - Products under Development by Companies 21
Esophageal Cancer - Products under Investigation by Universities/Institutes 26
Esophageal Cancer - Companies Involved in Therapeutics Development 27
Adaptimmune Therapeutics Plc 27
Advantagene, Inc. 28
Advaxis, Inc. 29
Advenchen Laboratories, LLC 30
Almac Discovery Limited 31
Amgen Inc. 32
ArQule, Inc. 33
Array BioPharma Inc. 34
Aslan Pharmaceuticals Pte. Ltd. 35
ATLAB Pharma SAS 36
Bayer AG 37
Betta Pharmaceuticals Co. Ltd. 38
Boehringer Ingelheim GmbH 39
Celgene Corporation 40
Celldex Therapeutics, Inc. 41
Cellectar Biosciences, Inc. 42
Cerulean Pharma, Inc. 43
Cyclacel Pharmaceuticals, Inc. 44
Genmab A/S 45
Glycotope GmbH 46
Hutchison MediPharma Limited 47
Ignyta, Inc. 48
ImmunoFrontier, Inc. 49
ImmunoGen, Inc. 50
Immunomedics, Inc. 51
Johnson & Johnson 52
Karyopharm Therapeutics, Inc. 53
Komipharm International Co., Ltd. 54
MacroGenics, Inc. 55
Mebiopharm Co., Ltd. 56
MedImmune, LLC 57
Merck & Co., Inc. 58
Novartis AG 59
Omeros Corporation 60
Omnitura Therapeutics Inc. 61
Oncolys BioPharma Inc. 62
Ono Pharmaceutical Co., Ltd. 63
Pfizer Inc. 64
Proteo, Inc. 65
Puma Biotechnology, Inc. 66
Shenzen SiBiono GeneTech Co., Ltd. 67
Shionogi & Co., Ltd. 68
Sihuan Pharmaceutical Holdings Group Ltd. 69
Spectrum Pharmaceuticals, Inc. 70
Symphogen A/S 71
Synta Pharmaceuticals Corp. 72
Taiho Pharmaceutical Co., Ltd. 73
Taiwan Liposome Company, Ltd. 74
Takara Bio Inc. 75
tella Inc 76
TG Therapeutics, Inc. 77
Transgene Biotek Limited 78
VioQuest Pharmaceuticals, Inc. 79
Virocan Therapeutics Private Limited 80
Esophageal Cancer - Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Combination Products 82
Assessment by Target 83
Assessment by Mechanism of Action 88
Assessment by Route of Administration 92
Assessment by Molecule Type 94
Drug Profiles 96
(tipiracil hydrochloride + trifluridine) - Drug Profile 96
1-BB1 - Drug Profile 99
ADXS-HER2 - Drug Profile 100
afatinib dimaleate - Drug Profile 102
AL-3818 - Drug Profile 107
ALM-301 - Drug Profile 109
alpelisib - Drug Profile 111
AMG-337 - Drug Profile 113
apatinib - Drug Profile 114
ATL-101 - Drug Profile 117
binimetinib - Drug Profile 119
CDX-1401 - Drug Profile 124
Cellular Immunotherapy for Oncology - Drug Profile 126
Cellular Immunotherapy for Oncology - Drug Profile 127
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 128
Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile 129
cetuximab biobetter - Drug Profile 130
CGX-1321 - Drug Profile 131
CRLX-101 - Drug Profile 132
CYC-140 - Drug Profile 135
Cytokine Induced Killer Cells + Dendritic Cells - Drug Profile 136
dacomitinib - Drug Profile 137
DKN-01 - Drug Profile 140
donafenib - Drug Profile 142
durvalumab - Drug Profile 143
elgemtumab - Drug Profile 147
erdafitinib - Drug Profile 149
futuximab - Drug Profile 151
ganetespib - Drug Profile 153
gedatolisib - Drug Profile 158
Gene Therapy for Esophageal Cancer - Drug Profile 160
Gene Therapy to Activate p53 for Oncology - Drug Profile 161
GSK-3377794 - Drug Profile 162
HMPL-309 - Drug Profile 165
I131-CLR1404 - Drug Profile 166
icotinib hydrochloride - Drug Profile 168
IMF-001 - Drug Profile 169
IMGN-289 - Drug Profile 170
KML-001 - Drug Profile 171
margetuximab - Drug Profile 173
MBP-426 - Drug Profile 175
MMD-37K - Drug Profile 177
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile 178
MVXONCO-1 - Drug Profile 179
neratinib - Drug Profile 180
nimotuzumab - Drug Profile 185
nintedanib - Drug Profile 189
nivolumab - Drug Profile 195
OBP-301 - Drug Profile 203
OMN-54 - Drug Profile 205
paclitaxel albumin bound - Drug Profile 207
panitumumab - Drug Profile 211
pasireotide ER - Drug Profile 214
PCA-062 - Drug Profile 216
pembrolizumab - Drug Profile 217
pralatrexate - Drug Profile 227
rAAVVICN-003 - Drug Profile 230
RXDX-106 - Drug Profile 231
S-222611 - Drug Profile 233
S-588410 - Drug Profile 235
sacituzumab - Drug Profile 237
selinexor - Drug Profile 239
sirotinib - Drug Profile 245
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 246
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 247
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 248
SMYD-2BAY02 - Drug Profile 249
TBI-1201 - Drug Profile 250
TBL-0805E - Drug Profile 252
TGR-1202 - Drug Profile 253
tiprelestat - Drug Profile 256
tisotumab vedotin - Drug Profile 259
tivantinib - Drug Profile 261
TLC-388 - Drug Profile 264
triciribine phosphate - Drug Profile 266
Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile 269
varlitinib - Drug Profile 270
Esophageal Cancer - Recent Pipeline Updates 273
Esophageal Cancer - Dormant Projects 426
Esophageal Cancer - Discontinued Products 431
Esophageal Cancer - Product Development Milestones 432
Featured News & Press Releases 432
Appendix 441
Methodology 441
Coverage 441
Secondary Research 441
Primary Research 441
Expert Panel Validation 441
Contact Us 441
Disclaimer 442

List of Tables
Number of Products under Development for Esophageal Cancer, H1 2016 17
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2016 32
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 33
Esophageal Cancer - Pipeline by Advantagene, Inc., H1 2016 34
Esophageal Cancer - Pipeline by Advaxis, Inc., H1 2016 35
Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 36
Esophageal Cancer - Pipeline by Almac Discovery Limited, H1 2016 37
Esophageal Cancer - Pipeline by Amgen Inc., H1 2016 38
Esophageal Cancer - Pipeline by ArQule, Inc., H1 2016 39
Esophageal Cancer - Pipeline by Array BioPharma Inc., H1 2016 40
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 41
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 42
Esophageal Cancer - Pipeline by Bayer AG, H1 2016 43
Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 44
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 45
Esophageal Cancer - Pipeline by Celgene Corporation, H1 2016 46
Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 47
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 48
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 49
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 50
Esophageal Cancer - Pipeline by Genmab A/S, H1 2016 51
Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2016 52
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 53
Esophageal Cancer - Pipeline by Ignyta, Inc., H1 2016 54
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H1 2016 55
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H1 2016 56
Esophageal Cancer - Pipeline by Immunomedics, Inc., H1 2016 57
Esophageal Cancer - Pipeline by Johnson & Johnson, H1 2016 58
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 59
Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016 60
Esophageal Cancer - Pipeline by MacroGenics, Inc., H1 2016 61
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016 62
Esophageal Cancer - Pipeline by MedImmune, LLC, H1 2016 63
Esophageal Cancer - Pipeline by Merck & Co., Inc., H1 2016 64
Esophageal Cancer - Pipeline by Novartis AG, H1 2016 65
Esophageal Cancer - Pipeline by Omeros Corporation, H1 2016 66
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 67
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016 68
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 69
Esophageal Cancer - Pipeline by Pfizer Inc., H1 2016 70
Esophageal Cancer - Pipeline by Proteo, Inc., H1 2016 71
Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016 72
Esophageal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 73
Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016 74
Esophageal Cancer - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 75
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 76
Esophageal Cancer - Pipeline by Symphogen A/S, H1 2016 77
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 78
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 79
Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 80
Esophageal Cancer - Pipeline by Takara Bio Inc., H1 2016 81
Esophageal Cancer - Pipeline by tella Inc, H1 2016 82
Esophageal Cancer - Pipeline by TG Therapeutics, Inc., H1 2016 83
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H1 2016 84
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2016 85
Esophageal Cancer - Pipeline by Virocan Therapeutics Private Limited, H1 2016 86
Assessment by Monotherapy Products, H1 2016 87
Assessment by Combination Products, H1 2016 88
Number of Products by Stage and Target, H1 2016 90
Number of Products by Stage and Mechanism of Action, H1 2016 95
Number of Products by Stage and Route of Administration, H1 2016 99
Number of Products by Stage and Molecule Type, H1 2016 101
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 279
Esophageal Cancer - Dormant Projects, H1 2016 432
Esophageal Cancer - Dormant Projects (Contd..1), H1 2016 433
Esophageal Cancer - Dormant Projects (Contd..2), H1 2016 434
Esophageal Cancer - Dormant Projects (Contd..3), H1 2016 435
Esophageal Cancer - Dormant Projects (Contd..4), H1 2016 436
Esophageal Cancer - Discontinued Products, H1 2016 437

List of Figures
Number of Products under Development for Esophageal Cancer, H1 2016 17
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Products, H1 2016 26
Assessment by Monotherapy Products, H1 2016 87
Assessment by Combination Products, H1 2016 88
Number of Products by Top 10 Targets, H1 2016 89
Number of Products by Stage and Top 10 Targets, H1 2016 89
Number of Products by Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Top 10 Routes of Administration, H1 2016 98
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 98
Number of Products by Top 10 Molecule Types, H1 2016 100
Number of Products by Stage and Top 10 Molecule Types, H1 2016 100